About: Pharmacogenomics of Viral Diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacogenomics of Viral Diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Pharmacogenomics of Viral Diseases
Creator	Dwivedi, Shailendra Khattri, Sanjay Singh, • Singh, Manish Pant, Kamlesh Dwivedi, S Khattri, S Pant, K Shukla, Shailja Shukla, • Singh Yadav, Suraj Yadav, •
source	PMC
abstract	Viral diseases are leading cause of deaths worldwide as WHO report suggests that hepatitis A virus (HAV) infects more than 80 % of the population of many developing countries. Viral hepatitis B (HBV) affects an estimated 360 million people, whereas hepatitis C affects 123 million people worldwide, and last but not least, at current, India has an HIV/AIDS population of approximately 2.4 million people and more than 30 million in whole world and now it has become a reason for 1.8 million death globally; thus, millions of people still struggle for their lives. The progress in medical science has made it possible in overcoming the various fatal diseases such as small pox, chicken pox, dengue, etc., but human immunodeficiency viruses, influenza, and hepatitis virus have renewed challenge surprisingly. The obstacles and challenges in therapy include existence of antibiotic resistance strains of common organisms due to overuse of antibiotics, lack of vaccines, adverse drug reaction, and last but not least the susceptibility concerns. Emergence of pharmacogenomics and pharmacogenetics has shown some promises to take challenges. The discovery of human genome project has opened new vistas to understand the behaviors of genetic makeup in development and progression of diseases and treatment in various viral diseases. Current and previous decade have been engaged in making repositories of polymorphisms (SNPs) of various genes including drug-metabolizing enzymes, receptors, inflammatory cells related with immunity, and antigen-presenting cells, along with the prediction of risks. The genetic makeup alone is most likely an adequate way to handle the therapeutic decision-making process for previous regimen failure. With the introduction of new antiviral therapeutic agents, a significant improvement in progression and overall survival has been achieved, but these drugs have shown several adverse responses in some individuals, so the success is not up to the expectations. Research and acquisition of new knowledge of pharmacogenomics may help in overcoming the prevailing burden of viral diseases. So it will definitely help in selecting the most effective therapeutic agents, effective doses, and drug response for the individuals. Thus, it will be able to transform the laboratory research into the clinical bench side and will also help in understanding the pathogenesis of viral diseases with drug action, so the patients will be managed more properly and finally become able to fulfill the promise of the future.
has issue date	2013-06-11(xsd:dateTime)
bibo:doi	10.1007/978-81-322-1184-6_28
has license	no-cc
sha1sum (hex)	03f66e024d4c560bc03d460ad8042344b670ac9c
schema:url	https://doi.org/10.1007/978-81-322-1184-6_28
resource representing a document's title	Pharmacogenomics of Viral Diseases
has PubMed Central identifier	PMC7120516
schema:publication	Omics for Personalized Medicine
resource representing a document's body	covid:03f66e024d4c560bc03d460ad8042344b670ac9c#body_text
is schema:about of	named entity 'hepatitis C' named entity 'Diseases' named entity 'REPORT' named entity 'BUT' named entity 'LEADING' named entity 'CURRENT' named entity 'ESTIMATED' named entity 'HEPATITIS C' named entity 'APPROXIMATELY' named entity 'INFECTS' named entity '360' named entity 'GLOBALLY' named entity 'REASON FOR' named entity 'HIV' named entity 'VIRAL DISEASES' named entity 'THEIR' named entity 'WORLD' named entity 'WORLDWIDE' named entity '1.8' named entity 'PHARMACOGENOMICS' named entity '2.4' named entity 'VIRAL HEPATITIS B' named entity 'CAUSE' named entity 'POPULATION' named entity 'DEATHS' named entity 'MILLION' named entity 'MORE THAN' named entity 'PEOPLE' named entity 'DEVELOPING COUNTRIES' named entity 'DEATH' named entity 'VIRAL DISEASES' named entity 'LIVES' named entity 'INDIA' named entity 'HEPATITIS A VIRUS' named entity 'diseases' named entity 'Viral hepatitis' named entity 'worldwide' named entity 'phenotype' named entity 'co-crystal' named entity 'FDA' named entity 'cell-surface receptors' named entity 'amino acids' named entity 'recurrent respiratory papillomatosis' named entity 'genomic approaches' named entity 'HPV' named entity 'cellular immune responses' named entity 'protease inhibitors' named entity 'vaccine' named entity 'efavirenz' named entity 'Cirrhosis' named entity 'renal dysfunction' named entity 'CYP2B6' named entity 'L1-L2' named entity 'viral infection' named entity 'virus' named entity 'immunological' named entity 'hepatocyte' named entity 'gene' named entity 'replication of viruses' named entity 'tenofovir' named entity 'vaccine studies' named entity 'viral load' named entity 'tenofovir' named entity 'viremia' named entity 'therapeutic agents' named entity 'cross-resistance' named entity 'ordered sequential' named entity 'tetravalent' named entity 'peptides' named entity 'IL28B' named entity 'proviral' named entity 'cell cycle regulation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software